← Back to Search

Observational for Prostate Adenocarcinoma

N/A
Waitlist Available
Led By John B. Kisiel, M.D.
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights

Study Summary

This study explores the potential use of DNA markers in the detection of prostate cancer and patient perceptions of this screening approach and other current or future prostate cancer screening and diagnostic tests.

Eligible Conditions
  • Prostate Adenocarcinoma
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Accuracy of methylated DNA markers (MDMs) for detection of cancer of the prostate (CAP)
Secondary outcome measures
Accuracy of CAP detection
Comparison of sample volumes

Trial Design

1Treatment groups
Experimental Treatment
Group I: ObservationalExperimental Treatment1 Intervention
PHASE I: Participants undergo urine sample collection on study. PHASE II: Participants undergo standard prostate massage and collection of prostatic fluid and urine samples on study. All participants complete a questionnaire and have their medical records reviewed on study.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,221 Previous Clinical Trials
3,768,840 Total Patients Enrolled
John B. Kisiel, M.D.Principal InvestigatorMayo Clinic in Rochester
3 Previous Clinical Trials
16,350 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine
2018. "DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06347809.
All > Paid Studies Minneapolis
~138 spots leftby Feb 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top